Clinical Trial12 May 2026, 03:06 pm
Suven Life Sciences: Masupirdine Phase 3 Trial Reaches 76% Enrollment
AI Summary
Suven Life Sciences announced that its Global Phase 3 trial of Masupirdine (SUVN-502) for agitation in Alzheimer’s dementia has reached a 76% enrollment milestone. The 375-patient study (NCT05397639, EudraCT Number 2021-003405-22) is being conducted across North America and Europe. The company anticipates completing patient enrollment by the end of 2026, with data readout expected by April 2027. Masupirdine is a selective 5-HT6 receptor antagonist aimed at treating agitation in Alzheimer's patients.
Key Highlights
- Suven Life Sciences' Phase 3 trial of Masupirdine reaches 76% enrollment.
- Patient enrollment is expected to complete by the end of 2026.
- Data readout from the Phase 3 trial is anticipated by April 2027.
- The study is a multi-center, randomized, double-blind, placebo-controlled trial.
- Masupirdine targets agitation in Alzheimer’s dementia via 5-HT6 receptor antagonism.